Bulk-to-Pack Traceability

Many products are made in two stages: a bulk batch is manufactured in a vessel, held, then filled into tubes, jars, bottles or blisters on a packaging line, sometimes over several days and in several pack sizes or customer presentations. Bulk-to-pack traceability is the record that joins the two stages, so each finished lot can be traced to its bulk batch and each bulk batch to all the finished lots and customers it reached.

What the record needs: the bulk batch number and its release or quarantine status at the time of filling, the hold time between manufacture and fill against the approved limit, the filling line and line clearance, the packaging component and printed label lots issued, in-process fill-weight or volume checks, and the quantities filled, rejected, sampled and left over. Bulk left over at the end of a fill needs its own status and must not slip into another batch without an approved procedure.

In US drug cGMP, the batch record must document each significant step, including packaging (21 CFR 211.188), packaging and labelling operations must prevent mix-ups and be inspected before use (21 CFR 211.130), labels must be issued and reconciled (21 CFR 211.125), and time limits for production stages apply where appropriate (21 CFR 211.111).

A worked example: a 500 kg cream batch is filled into 30 g and 60 g tubes for two customers across two shifts. That creates four packaged lots from one bulk batch. A complaint about one 60 g lot needs to reach the bulk batch's mixing and in-process records, and then forward to the other three packaged lots, within minutes rather than by reading paper records.

Related concepts: ointment vs cream vs gel, line clearance, yield reconciliation, hold-time study and batch manufacturing record. Sources: 21 CFR Part 211.